A bold deal announced this week has shown that Amgen (Nasdaq: AMGN) is not limiting its efforts to make a serious dent with its biosimilars to western markets.
The US biotech company has signed a deal with Chinese drugmaker Simcere Pharmaceutical Group to co-develop and commercialize four biosimilars in China.
"This partnership between a world-renowned biotechnology company and a leading Chinese pharma will help to accelerate development and launch of US and European-approved biosimilars in China"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze